Mark-Stejbach serves as Chief Commercial Officer at Alkermes and is responsible for all aspects of Alkermes’ commercial functions, including sales, marketing, managed care and trade channels, commercial analytics, public policy and the development of commercial strategy for the company’s proprietary pipeline. Mr. Stejbach has more than 25 years of experience in biotech and pharmaceutical marketing, sales, managed care, and finance. Prior to joining Alkermes, Mr. Stejbach served at Tengion, Inc. from 2008 to 2012, most recently as Chief Commercial Officer. He previously held senior positions at Merck & Co. and Biogen Idec Inc. He currently serves on the Board of Directors of Flexion Therapeutics. Mr. Stejbach received his MBA from The Wharton School, University of Pennsylvania and a Bachelor of Science in mathematics from Virginia Tech.   Mark-Stejbach serves as Chief Commercial Officer at Alkermes and is responsible for all aspects of Alkermes’ commercial functions, including sales, marketing, managed care and trade channels, commercial analytics, public policy and the development of commercial strategy for the company’s proprietary pipeline. Mr. Stejbach has more than 25 years of experience in biotech and pharmaceutical marketing, sales, managed care, and finance. Prior to joining Alkermes, Mr. Stejbach served at Tengion, Inc. from 2008 to 2012, most recently as Chief Commercial Officer. He previously held senior positions at Merck & Co. and Biogen Idec Inc. He currently serves on the Board of Directors of Flexion Therapeutics. Mr. Stejbach received his MBA from The Wharton School, University of Pennsylvania and a Bachelor of Science in mathematics from Virginia Tech.  

Pharmaceutical Industry